OTC Acne Treatment Labels Should Add Sensitivity Test Direction – FDA
This article was originally published in The Tan Sheet
OTC topical acne drug product manufacturers have an option to add label directions for sensitivity testing for new users of their products, “to reduce the risk of serious hypersensitivity reactions,” the FDA says.
You may also be interested in...
A recent uptick in the number of adverse events reported for benzoyl peroxide and salicylic acid products has pushed the regulatory agency to take a closer look at the potential for safety issues.
FDA ODSP details “data, research results, and other information” it needs on NAC that could sway proposing a rulemaking to allow its continued use in supplements. One detail missing is what the agency’s asking for are NDI notifications for NAC.
Procter & Gamble and Amazon are among nine companies FTC ordered to provide detailed information to help the agency identify causes behind ongoing supply chain disruptions. Chairwoman Khan says the information should “shed light on market conditions and business practices that may have worsened these disruptions.”